argenx Stops Thyroid Eye Disease Studies
argenx discontinues Phase 3 trials of efgartigimod SC for thyroid eye disease after independent review finds treatment unlikely to meet goals. Safety profile remained favorable.
/ 907 items
#Healthcare↓
FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT
Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.
Anavex Faces Setback in EU Alzheimer's Drug Review
Anavex Life Sciences receives negative EU opinion for blarcamesine Alzheimer's treatment but plans to request re-examination with new reviewers.
LENZ Stock Plunges After Retinal Tear Case Linked to VIZZ Eye Drops
LENZ Therapeutics shares dropped 27% following reports of a retinal tear associated with VIZZ presbyopia treatment, raising investor safety concerns despite company reassurances.
ImmunityBio Shares Jump on European Bladder Cancer Treatment Recommendation
ImmunityBio stock climbed 8.5% after European regulators recommended approval for Anktiva, a bladder cancer treatment that helped over 70% of patients in clinical trials.
Guggenheim Upgrades Bristol Myers to Buy with $62 Target
Guggenheim raises Bristol Myers to Buy, citing low expectations, strong pipeline, and potential entry point for value-focused investors.